NeoStem to Present at Multiple January Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Aegis Capital Boosts PT on Neostem (NBS) to $23; Positive AMR-001 Phase 2 is Potential Value Driver
January 2, 2014 10:58 AM ESTAegis Capital maintains its Buy rating on NeoStem, Inc. (Nasdaq: NBS), but raises its price target from $21 up to $23.
Analyst Ram Selvaraju noted that the price target change on NeoStem was based fundamentally upon the progress made recently with the Athelos technology in the domain of... More
